Merck closes SciBrunch KRAS licence for up to US$2.13B
Merck & Co. has closed a licence agreement with SciBrunch Therapeutics for worldwide rights to a preclinical KRAS G12D cancer drug, SPR2015, for up to $2.13B, including a $400M upfront payment. The deal includes potential milestone payments tied to development and commercialization. Merck shares traded at $147.79 on Sept. 28, with a $400M pre-tax charge expected in Q3 2026 results.
How this was made
The 30-second read
Why it matters
The deal adds a potentially valuable asset to Merger's oncology pipeline but introduces a near‑term earnings charge, creating mixed short‑term price pressure and long‑term upside potential.
Market read
Merck's large licence transaction is a primary corporate event with material financial impact, relevant for traders evaluating short‑term price moves and long‑term pipeline exposure.
What to watch
Milestone payments are contingent; timing and regulatory risk for KRAS G12D inhibitors remain uncertain.
Background
Merck announced the closure of a licence with Shanghai‑based SciBrunch Therapeutics for the pre‑clinical KRAS G12D inhibitor SPR2015, with a $400M upfront payment and a $0.13 per‑share charge to Q3 2026 results.
Ticker impact
Merck closed a licence with SciBrunch for up to $2.13B, paying $400M upfront and incurring a $0.13‑per‑share pre‑tax charge.
likely short‑term downside as the $0.13 charge is priced in, with potential medium‑term upside if SPR2015 progresses.
The deal size is material ($2.13B potential) and the charge is disclosed for the current quarter, creating an immediate earnings impact.
Market effects
Adds a high‑value KRAS asset to Merck's oncology pipeline, potentially raising competitive pressure on other KRAS developers.
U.S. pharma sector may see modest re‑rating as Merck's deal highlights continued M&A activity.
Large cross‑border licence (U.S. to China) underscores growing biotech collaborations, but limited immediate global market effect.
Counterpoint
The upfront $400M and $0.13 charge could outweigh long‑term upside if SPR2015 fails to clear clinical milestones.
Key entities
- companyMerck & Co., Inc.
U.S. pharmaceutical company executing the licence deal.
- companySciBrunch Therapeutics Co., Ltd.
Shanghai‑based drug developer granting the licence.
